Quarterly Activities Report
for the period ending 30 June 2026

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to present its activities report for the quarter ended 30 June 2026 (Q4 FY2026), together with its Appendix 4C Quarterly Cash Flow Report.

During the quarter, Neurotech's activities were focused on execution of its NTI164 development strategy, with workstreams spanning clinical operations, regulatory preparation, scientific validation and partnering engagement across its paediatric neurological disorder pipeline.

The Company's principal operational focus remains the Phase 3 "Beyond Harmony" trial in paediatric patients with autism spectrum disorder. Activities during the period were directed toward supporting trial execution, including patient screening and recruitment processes, site coordination, trial governance, clinical operations, drug supply and engagement with clinical and regulatory advisers. This work underpins the Company's broader objective of advancing NTI164 toward potential registration as a treatment targeting core symptoms of autism spectrum disorder.

Neurotech also progressed regulatory readiness activities for NTI164, supported by the favourable safety and tolerability profile observed across its preclinical and clinical development package to date. These activities are directed toward strengthening the Company's IND/TGA-enabling data package and supporting future regulatory engagement in Australia and overseas.

Neurotech Receives FDA IND Clearance

Subsequent to the end of the quarter, the US Food and Drug Administration (FDA) cleared Neurotech's Investigational New Drug (IND) submission for NTI164. In clearing the IND, the FDA reviewed the Company's nonclinical, chemistry, manufacturing and controls (CMC), and clinical protocol package, and raised no objection to the US IND study proceeding as designed.

In parallel, Neurotech continues to engage proactively with the Australian Therapeutic Goods Administration (TGA) to keep its Australian and US regulatory strategies aligned. These parallel interactions with the FDA and TGA are shaping a single global development pathway for NTI164, with a focus on generating clinical data capable of supporting submissions across multiple jurisdictions.

Together, the Australian Phase 3 trial, the US IND program and ongoing engagement with both regulators are expected to deliver an integrated efficacy, safety, pharmacokinetic and regulatory evidence package to support the Company's global development, registration and commercialisation strategies for NTI164.

Notice of Allowance secured for two U.S. patent applications

Subsequent to the end of the quarter, the Company announced that the United States Patent and Trademark Office (USPTO) had sent Notices of Allowance for U.S. patent applications No. 18/698,605 and No. 19/335,945. These applications relate to key aspects of the Company's NTI164 product and are both titled "Compositions and Methods for Treating Neurological Disorders".

Neurotech International Ltd
Suite 102 / Level 1, 55 Collins Street,
Melbourne, VIC 3000

T: 03 9498 3132
E: info@neurotechinternational.com
W: neurotechinternational.com

ABN: 73 610 205 402
ASX: NTI

The allowed claims of U.S. Patent Application No. 18/698,605 cover methods of reducing neuroinflammation using NTI164 and the allowed claims of U.S. Patent Application No. 19/335,945 are specifically directed to methods of treating autism spectrum disorder (ASD).

Once granted, these patents are expected to further strengthen Neurotech's intellectual property portfolio for NTI164, which is currently in Phase 3 clinical development for the treatment of ASD in paediatric patients.

Authorised Prescriber program update

The NTI164 Authorised Prescriber (AP) Program continued to expand during the quarter, with the network now operating across seven clinical sites nationally. This represents an increase from six sites at the end of the prior quarter and reflects sustained clinician engagement with the program.

Demand for access under the program remains strong. To date, more than 200 patients have been referred and are awaiting clinical review and subsequent supply of NTI164. Patient referrals are managed through the treating AP clinician at each site, with clinical review scheduled in line with site capacity.

The program provides direct benefits to the Company. It builds a longitudinal safety and tolerability dataset in a real-world setting, complementary to the Company's registrational clinical program. It establishes prescriber familiarity and referral pathways ahead of any future marketing authorisation. The AP program has been designed to ensure patient access while being cost-neutral to the Company. Pricing has been set at a level that covers the cost of supply in addition to a modest margin.

Neurotech Advocacy Day

In May, Neurotech hosted its Advocacy Day, bringing together families, healthcare professionals, shareholders and other interested parties to hear about the Company's work and the real-world impact of NTI164.

Professor Michael Fahey, Principal Investigator of the NTI164 clinical trials, presented the program roadmap alongside clinical data from two trials in Autism Spectrum Disorder (ASD). Two mothers of children with ASD also spoke, sharing their lived experience of how NTI164 has affected their children's daily lives.

The event was well attended and very well received, with attendees engaging directly with the clinical team throughout. This Advocacy Day reflects Neurotech's ongoing commitment to open engagement with the patient and carer community, and the Company intends to hold similar events in future.

A replay of the full session is available via the Company's website at:

https://neurotechinternational.com/news-and-media/

To access the replay, click on the heading titled 'Neurotech Investor and Advocacy Day'.

Investor conferences

During the quarter, Neurotech presented at several investor conferences and events, including the Ignite Investment Summit in Hong Kong and the Gold Coast Investment Showcase.

As part of these events, Managing Director & CEO Dr Anthony Filippis discussed the Company's broad-spectrum oral cannabinoid therapy, NTI164, and the significant opportunity and potential ahead of the company.

Appendix 4C Commentary

During the quarter, the Company recorded total cash operating expenses (excluding revenue sources) of ~$1.9 million (Q3 FY2026: $2.2 million), consisting of research and development costs of ~$1.7 million (Q3 FY2026: $2.0 million), along with advertising, marketing, staff, administrative, and corporate costs of ~$0.2 million (Q3 FY2026: $0.2 million).

R&D expenditure during the quarter was primarily driven by continued investment in IND-enabling preclinical development and toxicology programs supporting regulatory submissions to both the FDA and TGA. Clinical expenditure related to ongoing extension-phase activities within the Phase II/III ASD program included participant maintenance and follow-up costs for those transitioning from prior trials, along with preparation and implementation of a multi-site Phase 3 program in paediatric ASD. Remaining expenditure covered drug product manufacturing and process development, quality and stability programs, and preclinical formulation work.

Total operating cash outflows for the quarter were ~$1.9 million (Q3 FY2026: cash outflows of $2.2 million).

The Company closed the quarter with cash and cash equivalents of ~$2.4 million (Q3 FY26: $4.3 million). Subsequent to the end of the quarter on 15 July 2026, Neurotech received $3.15 million from a loan secured against the Company's anticipated refundable research and development tax incentive offsets for FY2026 and FY2027 (ASX announcement: 15 July 2026).

Further, payments to related parties and their associates as detailed in Section 6 of the Appendix 4C totalled $168,000.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About NTI164

NTI164 is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. Preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation and upstream biological mechanisms implicated in neurodevelopmental disorders.

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric

Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit http://www.neurotechinternational.com.

Forward Looking Statements

This announcement includes forward-looking statements, including forward-looking statements relating to the future operation of the Company. These forward-looking statements are based on the Company's expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to subsequently update or revise the forward-looking statements made in this announcement to reflect the circumstances or events after the date of this announcement. There is no guarantee that the Phase 3 study will be successful or that NTI164 will receive regulatory approval. You are strongly cautioned not to place undue reliance on forward-looking statements.

Neurotech International Ltd
Suite 102 / Level 1, 55 Collins Street,
Melbourne, VIC 3000

T: 03 9498 3132
E: info@neurotechinternational.com
W: neurotechinternational.com

ABN: 73 610 205 402
ASX: NTI

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Neurotech International Limited

ABN	**Quarter ended ("current quarter")**
73 610 205 402	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	0	0
1.2	Payments for		
	(a) research and development	(1,781)	(7,813)
	(b) product manufacturing and operating costs	0	0
	(c) advertising and marketing	(49)	(204)
	(d) leased assets	0	0
	(e) staff costs	(105)	(418)
	(f) administration and corporate costs	(50)	(543)
1.3	Dividends received (see note 3)	0	0
1.4	Interest received	23	43
1.5	Interest and other costs of finance paid	(1)	(6)
1.6	Income taxes paid	0	0
1.7	Government grants and tax incentives (R&D Rebate)	0	4,734
1.8	Other (GST refunds)	0	0
1.9	**Net cash from / (used in) operating activities**	**(1,963)**	**(4,207)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	0	0
	(b) businesses	0	0
	(c) property, plant and equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
	(f) other non-current assets	0	0
2.2	Proceeds from disposal of:		
	(a) entities	0	0
	(b) businesses	0	0
	(c) property, plant and equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0
	(f) other non-current assets	0	0
2.3	Cash flows from loans to other entities	0	0
2.4	Dividends received (see note 3)	0	0
2.5	Other (provide details if material)	0	0
2.6	**Net cash from / (used in) investing activities**	**0**	**0**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	0	3,754
3.2	Proceeds from issue of convertible debt securities	0	0
3.3	Proceeds from exercise of options	0	0
3.4	Transaction costs related to issues of equity securities or convertible debt securities	0	(164)
3.5	Proceeds from borrowings	0	0
3.6	Repayment of borrowings	0	0
3.7	Transaction costs related to loans and borrowings	0	0
3.8	Dividends paid	0	0
3.9	Other (provide details if material)	0	0
3.10	**Net cash from / (used in) financing activities**	**0**	**3,590**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	4,378	3,032
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,963)	(4,207)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	0	0

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	0	3,590
4.5	Effect of movement in exchange rates on cash held	(1)	(1)
4.6	**Cash and cash equivalents at end of period**	**2,414**	**2,414**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	899	1,863
5.2	Call deposits	1,515	2,515
5.3	Bank overdrafts	0	0
5.4	Other (provide details)	0	0
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**2,414**	**4,378**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	168
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0

Payments at section 6. relate to director fees ($60,000), executive salaries ($105,000) and reimbursement ($3,000).

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	0	0
7.2	Credit standby arrangements	0	0
7.3	Other (please specify)	0	0
7.4	**Total financing facilities**	0	0

7.5	**Unused financing facilities available at quarter end**	0

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	1,963
8.2	Cash and cash equivalents at quarter end (item 4.6)	2,414
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	2,414
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	1.23

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

The Company expects the current level of net operating cash flows to be maintained in Q1 FY2027. The level of expenditure and operational activities will be managed in line with the Company's available funding.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

The Company continues to monitor its funding position and expenditure requirements closely. Subsequent to the end of the quarter, NTI received cash inflows of $3.15m from a loan against its FY26 and FY27 R&D Tax Incentives on 15 July 2026. The Company is also currently in a trading halt pending an announcement regarding a capital raising.

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
	Yes, refer to 8.6.2.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2026
.....

Authorised by: The Board of Directors
.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.